HGF/MET信号通路在非小细胞肺癌EGFR-TKI耐药性中的研究进展被引量：10

Research Progress of HGF/MET Signaling Pathway in EGFR-TKI Resistance in Non-small Cell Lung Cancer

下载PDF

导出

摘要肺癌是世界上最常见的恶性肿瘤之一,其中非小细胞肺癌约占80%。肝细胞生长因子(hepatocyte growth factor,HGF)/上皮间质转化因子(mesenchymal-epithelial transition factor,MET)信号通路在许多生物学进程中都发挥着多效性影响,然而,在多种类型的肿瘤中都观察到HGF/MET信号通路的异常激活,并且通过生长因子受体和其他致癌性基因受体通路促进细胞增殖和转移。近年来,HGF/MET信号通路的异常激活被认为是对表皮生长因子受体酪氨酸激酶抑制剂(epidermal growth factor receptor tyrosine kinase inhibitor,EGFR-TKI)产生耐药的一个重要原因。本文将重点阐述该通路异常激活与非小细胞肺癌患者EGFR-TKI耐药的联系。 Lung cancer is one ofthe most common malignant tumors ofthe world, andnon-smallcelllungcancer （NSCLC） makes up about 80%. The hepatocyte growth factor （HGF）/mesenchymal-epithelial transition factor （MET） signal pathway has pleiotropic effects on many biological processes. However, aberrant HGF/MET signal pathway activation has been observed in many tumor types, and promotes cellular proliferation and metastasis via growth factor receptors and other oncogenic receptor pathways. In recent years, aberrant HGF/MET signal pathway activation has been considered a key step of resistance to epidermal growth factor receptor tyrosine kinase inhibitor （EGFR-TKI） therapy. This review addresses how aberrant HGF/MET signal pathway activation being associated with drug resistance to EGFR-TKI therapy in NSCLC patients.

作者宋世龙毕明宏

机构地区蚌埠医学院第一附属医院肿瘤内科

出处《中国肺癌杂志》 CAS 北大核心 2014年第10期755-759,共5页 Chinese Journal of Lung Cancer

关键词 HGF MET 肺肿瘤 EGFR酪氨酸激酶抑制剂耐药 HGF MET Lung neoplasms EGFR-TKI Resistance

分类号 R734.2 [医药卫生—肿瘤]

引文网络
相关文献

参考文献40

1Ayoola A, Barochia A, Belani K, et al. Primary and acquired resistance toepidermal growth factor receptor tyrosine kinase inhibitors in non-smallcell lung cancer: an update. Cancer Invest, 2012,30(5): 433-446.
2Remon J, Moran T, Majem M, et al. Acquired resistance to epidermalgrowth factor receptor tyrosine kinase inhibitors in _EGFii-mutant non-small cell lung cancer: a new era begins. Cancer Treat Rev, 2014, 40(1):93-101.
3Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer:rationale and progress. Nat Rev Cancer, 2012,12(2): 89-103.
4Radtke S, Milanovic M,Rossre C, et al. ERK2 but not ERK1 mediatesHGF-induced motility in non-small cell lung carcinoma cell lines. J CellSci, 2013,126(11): 2381-2391.
5Gandino L, Longati P, Medieo E, et al. Phosphorylation of serine 985negatively regulates the hepatocyte growth factor receptor kinase. J BiolChem, 1994,269(3): 1815-1820.
6Li Y, Zhang S, Tang Z,et al. Silencing of c-Met by RNA interferenceinhibits the survival, proliferation, and invasion of nasopharyngealcarcinoma cells. Tumour Biol, 2011,32(6): 1217-1224.
7Matsumura Af Kubota T, Taiyoh H, et al. HGF regulates VEGFexpression via the c-Met receptor downstream pathways, PI3K/Akt,MAPK and STAT3, in CT26 murine cells. IntJ Oncol, 2013, 42(2):535-542.
8Comoglio PM, Giordano S, Trusolino L. Drug development of METinhibitors: targeting oncogene addiction and expedience. Nat Rev DrugDiscov, 2008; 7(6): 504-516.
9Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker andpotential therapeutic target in clear cell renal cell carcinoma. Ann Oncol,2013,24(2):343-349.
10Kyung HJ, Byung HP, Soon SH. Progress in cancer therapy targetingc-Met signaling pathway. Arch Pharm Res, 2012, 35(4): 595-604.